MedTrace Logo

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

NCT03826719 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-02-01

No results posted yet for this study

Summary

This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.

Conditions

Interventions

BIOLOGICAL

NBP607QIV

Purified inactivated influenza virus surface antigens of four strains(quadrivalent)

BIOLOGICAL

Agrippal

Influenza virus surface antigens of three strains(trivalent)

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Woo Joo Kim, MD, PhD · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-17
Primary Completion
2014-03-28
Completion
2014-03-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03826719 on ClinicalTrials.gov